Law360, New York (September 04, 2008, 12:00 AM ET) -- Hi-Tech Pharmacal Co. Inc. is asking a judge to force federal regulators to bar other generic-drug makers from the market for generic Cosopt until after the company has had 180 days of market exclusivity for the glaucoma drug.
In a motion filed Wednesday in the U.S. District Court for the District of Columbia, Hi-Tech says the U.S. Food and Drug Administration must be forced to withhold approval to other generics makers in order to preserve Hi-Tech's exclusivity rights under the Hatch-Waxman Act.
FDA plans to decide...
Hi-Tech Sues FDA To Get Generic Cosopt Exclusivity
To view the full article, take a free trial now.
